摘要
目的:了解急性缺血性脑卒中患者羟乙基淀粉200/0.5氯化钠注射液(以下简称"羟乙基淀粉200/0.5")应用情况,并进行循证医学评价,为临床合理应用羟乙基淀粉200/0.5提供依据。方法:收集北京大学第三医院神经内科2010年6月—2010年10月应用羟乙基淀粉200/0.5的缺血性脑卒中住院患者的病例资料,对羟乙基淀粉200/0.5应用的适应证、用法与用量、用药时间、疗程、安全性等进行调查,并根据药品说明书、治疗指南和临床研究证据对其应用进行评价。结果:共纳入86个病例,羟乙基淀粉200/0.5用于分水岭脑梗死符合相关指南,占5.8%(5/86)。用于多发脑梗死存在2b级证据,占5.8%(5/86);用于大脑中动脉梗死存在1a级证据,占55.8%(48/86);用于颈内动脉梗死仅存在4级证据,占2.3%(2/86)。有30.2%(26/86)的用药适应证缺乏临床研究证据。羟乙基淀粉用药疗程平均为(13.66±5.81)d,75.6%(65/86)的患者用药疗程超过说明书建议的10 d。单次用药剂量均为500 mL,滴速均为160～200 mL·h-1,快于说明书中规定的滴速。结论:部分缺血性脑卒中患者羟乙基淀粉200/0.5的应用尚缺乏循证医学证据的支持,且在用法和疗程方面存在与说明书不符之处。
OBJECTIVE： To investigate the application of hydroxyethyl NaC1 injection （hydroxyethyl starch 200/ 0. 5 injection for short ） for acute ischemic stroke, and to perform an evidence-based medical evaluation so as to provide reference for rational use of hydroxyethyl starch 200/0. 5 injection. METHODS： We collected the medical records of the patients with acute ischemic stroke in the department of nephrology of our hospital who were treated with hydroxyethyl starch 200/0. 5 from June 2010 to October 2010. The indication, usage and dosage, medication time, course of treatment and safety of hydroxyethyl starch 200/0. 5 were investigated, and the use of hydroxyethyl starch 200/0. 5 injection was evaluated in accordance with drug package insert, treatment guidelines and clinical research evidence. RESULTS ： A total of 86 cases were included. The treatment was in line with the related guidelines in 5.8% （5/86） cases in which hydroxyethyl starch 200/0. 5 was used for cerebral watershed infarction. Evidence of class 2b level was noted in 5.8% （5/86） cases in which hydroxyethyl starch 200/0. 5 was used for multiple-cerebral infarction, evidence of class la level in 55.8% （48/86） cases in which hydroxyethyl starch 200/0.5 was used for middle cerebral artery occlusion, and evidence of class 4 level in 2. 3% （2/86） cases in which hydroxyethyl starch 200/0. 5 was used for carotid artery occlusion. 30. 2% （26/86） used hydroxyethyl starch 200/0. 5 in the absence of clinical research evidence-based indications. Hydroxyethyl starch 200/0. 5 was used for an average of （ 13.66 ±5.81 ） days, and 65 （75.6%） used hydroxyethyl starch 200/0. 5 for a duration longer than 10 days as labeled in package inserts. Thesingle dose for all cases was 500 mL at an infusion rate of 160-200 mL ·h^-1 that was faster than the infusion rate as described by the package inserts. CONCLUSION： In some 0. 5 was used in the absence of clinical research evidence those labeled in package inserts. acute ischemic stroke cases, the hydroxyethyl starch 200/ and the usage and course of treatment were not in line with
出处
《中国医院用药评价与分析》
2012年第9期776-779,共4页
Evaluation and Analysis of Drug-use in Hospitals of China
